Synklino Overview

  • Founded
  • 2017
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 1

Synklino General Information


Developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Ole Maaløes Vej 3, 3
  • 2200 Copenhagen
  • Denmark
+45 20 00 00 00
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Synklino Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 29-Aug-2019 Completed Generating Revenue
To view Synklino’s complete valuation and funding history, request access »

Synklino Executive Team (4)

Name Title Board Seat Contact Info
Thomas Kledal Ph.D Co-Founder & Chief Executive Officer
Jette Sen Ph.D Chief Operating Officer
Mads Jeppesen Ph.D Co-Founder & CMC Project Director
Mette Rosenkilde Ph.D Co-Founder & Board Member
To view Synklino’s complete executive team members history, request access »

Synklino Board Members (3)

Name Representing Role Since
John Haurum MD Synklino Chairman 000 0000
Mads Laustsen Synklino Board Member 000 0000
Mette Rosenkilde Ph.D Synklino Co-Founder & Board Member 000 0000
To view Synklino’s complete board members history, request access »

Synklino Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioInnovation Institute (BII) Accelerator/Incubator Minority 000 0000 000000 0
To view Synklino’s complete investors history, request access »